Isolated lymph node recurrence in epithelial ovarian cancer: Recurrence with better prognosis?


Journal

European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654
Titre abrégé: Eur J Obstet Gynecol Reprod Biol
Pays: Ireland
ID NLM: 0375672

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 16 11 2019
revised: 14 04 2020
accepted: 20 04 2020
pubmed: 10 5 2020
medline: 6 3 2021
entrez: 9 5 2020
Statut: ppublish

Résumé

The aim of this study was to compare overall survival (OS) between women with isolated lymph node recurrence (ILNR) and those with isolated peritoneal localization of recurrence (ICR), in patients managed for epithelial ovarian cancer. Data from 1508 patients with ovarian cancer were collected retrospectively from1 January 2000 to 31 December 2016, from the FRANCOGYN database, pooling data from 11 centres specialized in ovary treatment. Median overall survival was determined using the Kaplan-Meier method. Univariate and multivariate analyses were performed to define prognostic factors of overall survival. Patients included had a first recurrence defined as ILNR or ICR during their follow up. 79 patients (5.2 %) presented with ILNR, and 247 (16.4 %) patients had isolated carcinomatosis recurrence. Complete lymphadenectomy was performed more frequently in the ILNR group vs. the ICR group (67.1 % vs. 53.4 %, p = 0.004) and the number of pelvic lymph nodes involved was higher (2.4 vs. 1.1, p = 0.008). The number of involved pelvic LN was an independent predictor of ILNR (OR = 1.231, 95 % CI [1.074-1.412], p = 0.0024). The 3-year and 5-year OS rates in the ILNR group were 85.2 % and 53.7 % respectively, compared to 68.1 % and 46.8 % in patients with ICR. There was no significant difference in terms of OS after initial diagnosis (p = 0.18). 3- year and 5-year OS rates after diagnosis of recurrence were 62.6 % and 15.6 % in the ILNR group, and 44 % and 15.7 % in patients with ICR (p = 0.21). ILNR does not seem to be associated with a better prognosis in terms of OS.

Identifiants

pubmed: 32381349
pii: S0301-2115(20)30234-7
doi: 10.1016/j.ejogrb.2020.04.049
pii:
doi:

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

64-69

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no conflict of interest

Auteurs

Romain Delangle (R)

Department of Gynaecology, Centre Hospitalier Universitaire de Tours, Tours, France.

Lauranne Rossard (L)

Department of Gynaecology, Centre Hospitalier Universitaire de Tours, Tours, France.

Julien Cirier (J)

Department of Gynaecology, Centre Hospitalier Universitaire de Tours, Tours, France.

Julie Delvallée (J)

Department of Gynaecology, Centre Hospitalier Universitaire de Tours, Tours, France; INSERM U1069 Université François-Rabelais, Tours, France.

Sofiane Bendifallah (S)

Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.

Cyril Touboul (C)

Department of Obstetrics and Gynaecology, Centre Hospitalier Intercommunal, Créteil, France.

Pierre Collinet (P)

Department of Gynaecological Surgery, Jeanne de Flandre University Hospital, Lille, France.

Charles Coutant (C)

Department of Surgical Oncology, Georges-Francois Leclerc Cancer Centre, Dijon, France.

Cherif Akladios (C)

Department of Surgical Gynaecology, University Hospital of Strasbourg, Strasbourg, France.

Vincent Lavoué (V)

Department of Gynaecological Surgery, Rennes University Hospital, Rennes, France.

Pierre-Adrien Bolze (PA)

Gynaecological Surgery Department, CHU Lyon-Sud, Pierre-Bénite, 69000 Lyon, France.

Cyrille Huchon (C)

Department of Gynaecology, Centre Hospitalier de Poissy, Poissy, France.

Alexandre Bricou (A)

Department of Gynaecology, Bobigny University, AP-HP, Hôpital Jean-Verdier, Bondy, France.

Geoffroy Canlorbe (G)

Department of Gynaecologic and Breast Surgery and Oncology, AP-HP, Pitié-Salpêtrière University Hospital, Paris, France.

Marcos Ballester (M)

Department of Gynaecologic and Breast Surgery, AP-HP, GH Diaconesses Croix Saint Simon, Paris, France.

Emile Darai (E)

Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.

Gilles Body (G)

Department of Gynaecology, Centre Hospitalier Universitaire de Tours, Tours, France; INSERM U1069 Université François-Rabelais, Tours, France.

Lobna Ouldamer (L)

Department of Gynaecology, Centre Hospitalier Universitaire de Tours, Tours, France; INSERM U1069 Université François-Rabelais, Tours, France. Electronic address: l.ouldamer@chu-tours.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH